Evidence map›Paper›PMID 41737488›Full record

ArticleFrontiers in oncology2026

Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China.

Wen Zhao, Peiyi Yang, Jing Qin, Cheng Huang, Hongjun Fan, Mei Jin, Chao Duan, Ying Wu, Xisi Wang, Chunying Cui and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wen ZhaoMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Peiyi YangMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jing QinMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Cheng HuangMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Hongjun FanMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Mei JinMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Chao DuanMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Ying WuMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Xisi WangMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Chunying CuiSchool of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Yan SuMedical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Real-world evidence on dinutuximab beta for high-risk neuroblastoma (NB) in the Chinese pediatric patients remains limited. This study evaluated clinical efficacy and safety of dinutuximab beta as first-line maintenance therapy in a real-world setting. Methods: We retrospectively analyzed pediatric patients newly diagnosed with high-risk NB who after induction and consolidation therapy, received dinutuximab beta combined with granulocyte-macrophage colony-stimulating factor and isotretinoin, with or without chemotherapy. The primary outcome was objective response rate (ORR); secondary outcomes included 1- and 2-year event-free survival (EFS) and overall survival (OS) rates, and safety. Results: Twenty-eight patients were included, with a median age of 56 months (range 27-113) at the initiation of dinutuximab beta. Prior to immunotherapy, 14 patients had achieved complete response (CR) and 14 partial response (PR). Among those with CR, the CR maintenance rate was 78.6% (11/14). In patients with PR, the ORR at the end of treatment (EOT) was 64.3% (9/14). Stratified by treatment modality, PR patients receiving dinutuximab beta with chemotherapy had a higher ORR than those treated with dinutuximab beta alone at EOT [70.0% (7/10) vs. 50.0% (2/4)]. Regarding autologous stem cell transplantation (ASCT) status, all 3 patients who underwent ASCT achieved CR at EOT (ORR: 100%), whereas the ORR among patients without ASCT was 54.5% (6/11). The overall 1-year and 2-year EFS rates were 88.2% [95% confidence interval (CI), 67.4-96.1%)] and 72.4% (95% CI, 41.4-88.8%), respectively; 1-year and 2-year OS rates were both 95.8% (95% CI, 73.9-99.4%). Adverse events (AEs) were common but mostly mild to moderate in severity. Grade 3 or higher AEs occurred predominantly in patients who received combination chemotherapy, including fever, neutropenia, and thrombocytopenia. Pain was effectively managed with most patients requiring only minimal oral morphine (0.01-0.05 mg/kg/d) during cycles 3-5. Conclusion: Dinutuximab beta shows favorable efficacy for pediatric patients with high-risk NB. Patients treated with prior ASCT or combined with chemotherapy showed trends toward improved response rates and survival outcomes, although optimal treatment regimens required further investigation. AEs are generally manageable, and the use of standardized pain assessment combined with multimodal analgesia has enabled a substantial reduction in morphine exposure.

Indexed as

dinutuximab betafirst-line maintenanceGD2- antibody immunotherapyhigh-risk neuroblastomapediatrics

Identifiers

PMID41737488
PMCPMC12926132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.